Edukimi:
Shtator-2000, Fillimi i studimeve per Mjekesi te Pergjithshme prane Fakultetit te 鈥淢edicina e Chirurgia鈥 ne 鈥淟鈥橴niversit脿 degli Studi di Roma La Sapienza鈥
15 Mars-2004 Fitues i te drejtes per 鈥淢jek Frekuentues鈥 prane 鈥淒ipartimento di Scienze Cardiovascolari, Respiratorie e Morfologiche鈥 I cattedra di Cardiologia, Policlinico Umberto I, L鈥橴niversita degli Studi di Roma La Sapienza.
29 Shtator-2006 Mbarimi i studimeve dhe Diplomimi ne 鈥淢jekesi dhe Kirurgji te pergjithshme鈥 prane l鈥橴niversit脿 degli Studi di Roma 鈥淟a Sapienza鈥 Relatore Prof. Carmine Dario Vizza Vleresimi final: 110/110 e lode.
10 Janar-2007 Abilitimi per te ushtruar profesionin e 鈥淢jekut Kirurg鈥 prane 鈥漧鈥橴niversit脿 degli Studi di Roma 鈥淟a Sapienza鈥, me vleresimin final: 270/270-esimi.
17 Prill-2007 I nenshkruar ne 鈥淥rdine dei Medici Chirurghi e Odontoiatri della Provincia di Roma dal N掳 d鈥檕rdine 55895鈥
20/03/2008鈥03/04/2012 Specializuar n毛 Kardiologji n毛 鈥滻 Scuola di Specializzazione in Cardiologia鈥 pran毛 鈥淚l Dipartimento di Scienze Cardiovascolari e Respiratorie, Policlinico Umberto I di Roma鈥 me vleresimin final 70/70 e lode.
2011 Fitues i cmimit 鈥淜ardiologu i ri鈥 me i mire ne 鈥淩egione Lazio鈥.
22 Nentor 2012-9 Nentor 2015 Kryerja e Doktoratur毛s n毛 鈥淔isiopatologia Angio-Cardio-Toracica ed Imaging鈥 cikli i 28, pran毛 鈥淒ipartimento di Scienze Cardiovascolari e Respiratorie, Policlinico Umberto I Rome鈥 dhe marrjen e titullit 鈥淒oktor Shkencash鈥 me vleresimin maksimal.
EKSPERIENCA PROFESIONALE
Nga 2004 deri ne 2013, pran毛 鈥淯niversit脿 degli Studi di Roma 鈥淟a Sapienza鈥, gjate frekuentimit si 鈥淢jek Frekuentues鈥 dhe gjate periudhes se specializimit ne Kardiologji, u jam dedikuar si aspekteve klinike, ashtu edhe diagnostikimit jo invaziv (TTE, eco-stress, test da sforzo, Holter ECG, Holter i presionit), semi-invaziv (TEE) dhe invaziv ( kateterizm kardiak i djatht毛, koronarografi diagnostikuese) t毛 pacientit kardiopatik si eksperienc毛 e p毛rditshme pune.
Nen-specializim ne degen e Kardiologjise persa i perket 鈥淜ardiologjise Intensiviste鈥 per nje periudhe 3-vjecare prane UTIC (Unita di Terapia Intensiva Cardiologica/Coronarica) I Catedra di Cardiologia, Policlinico Umberto I, Rome.
Gjate periudhes 2009-2013 eksperience pune si mjek Kardiolog prane 鈥淐asa di Cura Villa Mafalda鈥, Casa di Cura Villa Margherita鈥 dhe prane 鈥淐asa di Cura Villa Stuart, Rome鈥.
Nga periudha 2004-2013 pjese aktive e 鈥淐entro dell鈥 Ipertensione Arteriosa Polmonare e Forme Associate鈥, prane 鈥淧oliclinico Umberto I Rome鈥 si qender referimi ne Itali dhe ne Europe, duke konsiliduar nje eksperience te gjate ne diagnose dhe trajtim te pacientit me 鈥淚pertension Pulmonar鈥 dhe te tjera patologji kardiake te djathta ne pergjithesi.
AKTIVITETI KERKIMOR
Study coordinator per protokollin klinik internazional N掳 A1481243: 鈥淎 multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20 mg tid or placebo when added to bosentan in the treatment of subjects, aged 18 years and above, with pulmonary arterial hypertension (PAH)鈥
Study coordinator per protokollin klinik internazional N掳 A1481244: 鈥淎 multinational, multicentre, randomized, parallel group, double-blind study to assess the efficacy and safety of 1 mg, 5 mg, 20 mg TID of oral sildenafil in the treatment of subject aged 18 year and over with pulmonary arterial hypertension (PAH)鈥
Study coordinator per protokollin klinik internazional N掳 AC-055-302 (SERAPHIN): 鈥淎 multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients whit symptomatic pulmonary arterial hypertension鈥
Study coordinator per protokollin klinik internazional N掳 AC-055-303 (SERAPHIN-OL): 鈥淟ong- term single arm open-label extension study of the SERAPHIN study, to assess the safety and tolerability of ACT-064992 in patients with symptomatic pulmonary arterial hypertension鈥
Sub-investigator per protokollin klinik internazional N掳 11348 (CHEST-1): 鈥淩andomized, double-blind, multicenter, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patient with Chronic Thromboembolic Pulmonary hypertension (CTEPH)鈥
Sub-investigator per protokollin klinik internazional N掳 11349 (CHEST-2): 鈥淟ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patient with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)鈥
Sub-investigator per protokollin klinik internazional N掳 12934 (PATENT-1): 鈥淩andomized, double-blind, placebo-controlled, multicentre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)鈥
Sub-investigator per protokollin klinik internazional N掳 12935 (PATENT-2): 鈥淟ong-term extension, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)鈥
Study coordinator per protokollin klinik internazional N掳 A093 (ASCEND-HF): 鈥淒ouble-blind, placebo-controlled, multi center acute study of clinical effectiveness of nesiritide in subjects with decompensated heart failure鈥
Study coordinator per protokollin klinik internazional N掳 CK-LX3401 (BALANCE): 鈥淭reatment of hyponatriemia based on lixivaptan in NYHA class III/IV cardiac patient evaluation鈥
Study coordinator per protokollin klinik internazional N掳 CQTI571A2301 (IMPRES): 鈥淎 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficay Study鈥
Study coordinator per protokollin klinik internazional N掳 RLX.CHF.003 (Pre-RELAX-AHF/RELAX鈥 AHF): 鈥淎 phase II/III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of relaxin in subjects With Acute Heart Failure鈥
Sub-investigator per il protocollo clinico internazionale TDE-PH-308 (FREEDOM-C2): 鈥淎 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension鈥
PUBLIKIME:
Vizza CD, Letizia C, Badagliacca R, Poscia R, Pezzuto B, Gambardella C, Nona A, Papa S, Marcon S, Mancone M, Iacoboni C, Riccieri V, Volterrani M, Fedele F. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. Int J Cardiol. 2012 Jan 18. [Epub ahead of print] Index Pubmed
Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. Regul Pept. 2008 Nov 29;151(1-3):48-53. Epub 2008 Aug 16. Index Pubmed
Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance.Badagliacca R, Poscia R, Pezzuto B, Papa S, Nona A, Mancone M, Mezzapesa M, Nocioni M, Sciomer S, Valli G, Cedrone N, Fedele F, Vizza CD.Cardiology. 2012;121(2):76-82. doi: 10.1159/000336172. Epub 2012 Mar 15. Index Pubmed.
Right ventricular dyssynchrony in idiopathic pulmonary arterial hipertension: determinants and impact on pump function. Badagliacca R, Poscia R, Pezzuto B, Papa S, Gambardella C, Francone M, Mezzapesa M, Nocioni M, Nona A, Rosati R, Sciomer S, Fedele F, Dario Vizza C. J Heart Lung Transplant. 2015 Mar;34(3):381-9. doi: 10.1016/j.healun.2014.06.010. Epub 2014 Jun 21.Indexed Pubmed.
R. Poscia, C.D. Vizza, R. Badagliacca, A. Nona, C. Gambardella, E. Crescenzi, B. Pezzuto, S. Papa, S. Sciomer, F. Fedele Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing Bosentan. Societ脿 Italiana di Cardiologia 鈥 69掳 Congresso Nazionale (Roma, 13-16 dicembre 2008). Giornale Italiano di Cardiologia 2008; 9 (suppl. 1 al n. 12): C320. Abstract
R. Badagliacca, C.D. Vizza, C. Letizia, R. Poscia, E. Crescenzi, C. Gambardella, A. Nona, S. Papa, B. Pezzuto, S. Sciomer, F. Fedele Predictors of clinical worsening in patients with PAH treated with Bosentan. Societ脿 Italiana di Cardiologia 鈥 69掳 Congresso Nazionale (Roma, 13-16 dicembre 2008). Giornale Italiano di Cardiologia 2008; 9 (suppl. 1 al n. 12): C321 . Abstract
C.D. Vizza, R. Poscia, R. Badagliacca, A. Nona, E. Crescenzi, C. Gambardella, B. Pezzuto, F. Fedele Il trattamento medico dell鈥檌pertensione polmonare. Associazione Italiana Pneumologi Ospedalieri. Compendio 鈥 L鈥檌pertensione polmonare: aggiornamenti e novit脿 (dicembre 2008; pagg. 26-31.
C.D. Vizza, R. Badagliacca, M. Francone, R. Poscia, B. Pezzuto, S. Papa, S. Marcon, C. Gambardella, A. Nona and F. Fedele. Impact of RV Remodelling on Survival in PAH Patients: Role of RV Mass/Volume Ratio. Chest 2010; 138:928A Vizza C.D., Badagliacca R., Poscia R. , Nona A., Crescenzi E., Ciuffa M., Ferrante F., Sciomer S., Fedele F. Long term result of medical theraphy in patient with pulmonary arterial hypertension. Atti del X World Congress of echocardiography and Cardiovascular Imaging 19-21-oct 2006 Rome
